Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: A postmarketing survey

Japanese Journal of Clinical Oncology

Volumn 43, Issue 5, 2013, Pages 483-491

  Shiozawa, Tomoo ^a   Tadokoro, Jun ichi ^b   Fujiki, Toshitaka ^a   Fujino, Koji ^b   Kakihata, Koji ^a   Masatani, Shuji ^b   Morita, Satoshi ^c   Gemma, Akihiko ^d   Boku, Narikazu ^e  

^a DAIICHI SANKYO CO   (Japan)

^b Yakult Honsha Company Limited   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse drug reaction; Irinotecan; Postmarketing survey; Risk factor; Treatmentrelated death

Indexed keywords

IRINOTECAN;

ADULT; AGE DISTRIBUTION; ARTICLE; ASCITES; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EXPLANATORY VARIABLE; FEMALE; GENDER; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; LEUKOPENIA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVARY CANCER; PLEURA EFFUSION; POSTMARKETING SURVEILLANCE; SKIN CARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; UNIVARIATE ANALYSIS; UTERINE CERVIX CANCER;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEATH; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HUMANS; JAPAN; LEUKOPENIA; LOGISTIC MODELS; LUNG NEOPLASMS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SKIN NEOPLASMS; STOMACH NEOPLASMS; THROMBOCYTOPENIA;

EID: 84877342399     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt040     Document Type: Article

References (21)

1. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
2. Society of Japanese Pharmacopoeia. Summary Basis of Approval (SBA): No1 Irinotecan Hydrochloride (revised edition). Tokyo: Yakuji Nippo 1995.
3. Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Safety 2005;28:417-33.
4. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-26.
5. Tadokoro J, Kakihata K, Shimazaki M, et al. Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients. Jpn J Clin Oncol 2011;41:1101-11.
6. Evaluation Criteria Committee of the Japan Society for Cancer Therapy. Toxicity criteria. Nippon Gan Chiryo Gakkai Shi 1986;21:943-53 (in Japanese).
7. Vincenzi B, Schiavon G, Pantano F, Santini D, Tonini G. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat Clin Pract Oncol 2008;5:455-65.
8. Product Information: Topotecinw or Camptow injection, irinotecan hydrochloride injection. Tokyo, Japan: Daiichi-Sankyo Co. Ltd. or Yakult Honsha Co. Ltd 2010 (in Japanese).
9. Product Information: CAMPTOSAR (R) injection, irinotecan hydrochloride injection. New York, NY: Pfizer Inc. 2009.
10. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008;26:5721-7.
11. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002;20:1491-8.
12. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537-41.
13. Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 2009;63:115-20.
14. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801-7.
15. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001;345:144-5.
16. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
17. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006;24:2237-44.
18. Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1 ast 6 and ast 28. Pharmacogenet Genomics 2007;17: 497-504.
19. Inoue K, Hiraoka N, Kasamatsu Y. A case of irinotecan-induced pneumonitis. Jap J Lung Cancer 2000;40:219-21.
20. Madarnas Y, Webster P, Shoter AM, Bjarnason GA. Irinotecan-associated pulmonary toxicity. Anti-Cancer Drugs 2000;11:709-13.
21. Yoshii N, Suzuki T, Nagashima M, Kon A, Kakihata K, Gemma A. Clarification of clinical feature of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports. Anti-Cancer Drugs 2011;22:563-8.